デフォルト表紙
市場調査レポート
商品コード
1118233

世界のカンジダ症治療薬市場:考察と予測 (2028年まで)

Global Candidiasis Therapeutics Market Insights, Forecast to 2028

出版日: | 発行: QYResearch | ページ情報: 英文 136 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
世界のカンジダ症治療薬市場:考察と予測 (2028年まで)
出版日: 2022年08月24日
発行: QYResearch
ページ情報: 英文 136 Pages
納期: 2~3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、カンジダ症治療薬 (Candidiasis Therapeutics) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • カンジダ症治療薬の製品概要
  • 市場:タイプ別
    • 世界のカンジダ症治療薬の市場規模成長率:タイプ別, 2017 VS 2021 VS 2028
    • Doxorubicin
    • Cisplatin
    • 7Carboplatin
    • Etoposide
    • Ifosfamide
    • Cyclophosphamide
    • Methotrexate
    • Vincristine
  • 市場:アプリケーション別
    • 世界のカンジダ症治療薬の市場規模成長率:アプリケーション別, 2017 VS 2021 VS 2028
    • Multispecialty Hospitals
    • Cancer Research Institutes
    • Others
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界のカンジダ症治療薬の販売 推定および予測 2017-2028
  • 世界のカンジダ症治療薬の収益 推定および予測 2017-2028
  • 世界のカンジダ症治療薬の収益:地域別: 2017 VS 2021 VS 2028
  • 世界のカンジダ症治療薬の販売:地域別
    • 世界のカンジダ症治療薬の販売:地域別 (2017-2022)
    • 世界の販売 カンジダ症治療薬 :地域別 (2023-2028)
  • 世界のカンジダ症治療薬の収益:地域別
    • 世界のカンジダ症治療薬の収益:地域別 (2017-2022)
    • 世界のカンジダ症治療薬の収益:地域別 (2023-2028)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第3章 競合:メーカー別

  • 世界のカンジダ症治療薬の販売:メーカー別
    • 世界のカンジダ症治療薬の上位メーカー:販売別 (2017-2022)
    • 世界のカンジダ症治療薬の販売市場シェア:メーカー別 (2017-2022)
    • 世界の上位10・上位5メーカー: カンジダ症治療薬2021
  • 世界のカンジダ症治療薬の収益:メーカー別
    • 世界のカンジダ症治療薬の収益:メーカー別 (2017-2022)
    • 世界のカンジダ症治療薬の収益市場シェア:メーカー別 (2017-2022)
    • 世界の上位10・上位5企業: カンジダ症治療薬の収益 2021
  • 世界のカンジダ症治療薬の販売価格:メーカー別 (2017-2022)
  • 競合情勢の分析
    • メーカーの市場集中度 (CR5 and HHI)
    • 世界のカンジダ症治療薬の市場シェア:企業タイプ別 (Tier 1, Tier 2, and Tier 3)
    • 世界のカンジダ症治療薬のメーカーの地理的分布
  • M&A, 拡張計画

第4章 市場規模:タイプ別

  • 世界のカンジダ症治療薬の販売:タイプ別
    • 世界のカンジダ症治療薬の販売実績:タイプ別 (2017-2022)
    • 世界のカンジダ症治療薬の販売予測:タイプ別 (2023-2028)
    • 世界のカンジダ症治療薬の販売市場シェア:タイプ別 (2017-2028)
  • 世界のカンジダ症治療薬の収益:タイプ別
    • 世界のカンジダ症治療薬の収益実績:タイプ別 (2017-2022)
    • 世界のカンジダ症治療薬の収益予測:タイプ別 (2023-2028)
    • 世界のカンジダ症治療薬の収益市場シェア:タイプ別 (2017-2028)
  • 世界のカンジダ症治療薬の価格:タイプ別
    • 世界のカンジダ症治療薬の価格:タイプ別 (2017-2022)
    • 世界のカンジダ症治療薬の価格予測:タイプ別 (2023-2028)

第5章 市場規模:アプリケーション別

  • 世界のカンジダ症治療薬の販売:アプリケーション別
    • 世界のカンジダ症治療薬の販売実績:アプリケーション別 (2017-2022)
    • 世界のカンジダ症治療薬の販売予測:アプリケーション別 (2023-2028)
    • 世界のカンジダ症治療薬の販売市場シェア:アプリケーション別 (2017-2028)
  • 世界のカンジダ症治療薬の収益:アプリケーション別
    • 世界のカンジダ症治療薬の収益実績:アプリケーション別 (2017-2022)
    • 世界のカンジダ症治療薬の収益予測:アプリケーション別 (2023-2028)
    • 世界のカンジダ症治療薬の収益市場シェア:アプリケーション別 (2017-2028)
  • 世界のカンジダ症治療薬の価格:アプリケーション別
    • 世界のカンジダ症治療薬の価格:アプリケーション別 (2017-2022)
    • 世界のカンジダ症治療薬の価格予測:アプリケーション別 (2023-2028)

第6章 北米

  • 北米のカンジダ症治療薬 市場規模:タイプ別
    • 北米のカンジダ症治療薬の販売:タイプ別 (2017-2028)
    • 北米のカンジダ症治療薬の収益:タイプ別 (2017-2028)
  • 北米のカンジダ症治療薬 市場規模:アプリケーション別
    • 北米のカンジダ症治療薬の販売:アプリケーション別 (2017-2028)
    • 北米のカンジダ症治療薬の収益:アプリケーション別 (2017-2028)
  • 北米のカンジダ症治療薬 市場規模:国別
    • 北米のカンジダ症治療薬の販売:国別 (2017-2028)
    • 北米のカンジダ症治療薬の収益:国別 (2017-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州のカンジダ症治療薬 市場規模:タイプ別
    • 欧州のカンジダ症治療薬の販売:タイプ別 (2017-2028)
    • 欧州のカンジダ症治療薬の収益:タイプ別 (2017-2028)
  • 欧州のカンジダ症治療薬 市場規模:アプリケーション別
    • 欧州のカンジダ症治療薬の販売:アプリケーション別 (2017-2028)
    • 欧州のカンジダ症治療薬の収益:アプリケーション別 (2017-2028)
  • 欧州のカンジダ症治療薬 市場規模:国別
    • 欧州のカンジダ症治療薬の販売:国別 (2017-2028)
    • 欧州のカンジダ症治療薬の収益:国別 (2017-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 アジア太平洋

  • アジア太平洋のカンジダ症治療薬 市場規模:タイプ別
    • アジア太平洋のカンジダ症治療薬の販売:タイプ別 (2017-2028)
    • アジア太平洋のカンジダ症治療薬の収益:タイプ別 (2017-2028)
  • アジア太平洋のカンジダ症治療薬 市場規模:アプリケーション別
    • アジア太平洋のカンジダ症治療薬の販売:アプリケーション別 (2017-2028)
    • アジア太平洋のカンジダ症治療薬の収益:アプリケーション別 (2017-2028)
  • アジア太平洋のカンジダ症治療薬 市場規模:地域別
    • アジア太平洋のカンジダ症治療薬の販売:地域別 (2017-2028)
    • アジア太平洋のカンジダ症治療薬の収益:地域別 (2017-2028)
    • 中国
    • 日本
    • 韓国
    • インド
    • オーストラリア
    • 台湾
    • インドネシア
    • タイ
    • マレーシア
    • フィリピン

第9章 ラテンアメリカ

  • ラテンアメリカのカンジダ症治療薬 市場規模:タイプ別
    • ラテンアメリカのカンジダ症治療薬の販売:タイプ別 (2017-2028)
    • ラテンアメリカのカンジダ症治療薬の収益:タイプ別 (2017-2028)
  • ラテンアメリカのカンジダ症治療薬 市場規模:アプリケーション別
    • ラテンアメリカのカンジダ症治療薬の販売:アプリケーション別 (2017-2028)
    • ラテンアメリカのカンジダ症治療薬の収益:アプリケーション別 (2017-2028)
  • ラテンアメリカのカンジダ症治療薬 市場規模:国別
    • ラテンアメリカのカンジダ症治療薬の販売:国別 (2017-2028)
    • ラテンアメリカのカンジダ症治療薬の収益:国別 (2017-2028)
    • メキシコ
    • ブラジル
    • アルゼンチン

第10章 中東・アフリカ

  • 中東・アフリカのカンジダ症治療薬 市場規模:タイプ別
    • 中東・アフリカのカンジダ症治療薬の販売:タイプ別 (2017-2028)
    • 中東・アフリカのカンジダ症治療薬の収益:タイプ別 (2017-2028)
  • 中東・アフリカのカンジダ症治療薬 市場規模:アプリケーション別
    • 中東・アフリカのカンジダ症治療薬の販売:アプリケーション別 (2017-2028)
    • 中東・アフリカのカンジダ症治療薬の収益:アプリケーション別 (2017-2028)
  • 中東・アフリカのカンジダ症治療薬 市場規模:国別
    • 中東・アフリカのカンジダ症治療薬の販売:国別 (2017-2028)
    • 中東・アフリカのカンジダ症治療薬の収益:国別 (2017-2028)
    • トルコ
    • サウジアラビア

第11章 企業プロファイル

  • Novartis AG
  • Amgen
  • F. Hoffmann-La Roche Ltd.
  • Bayer-Algeta
  • Merrion Pharmaceuticals Plc.
  • Ablynx
  • Genta Incorporated
  • Galapagos NV
  • Catena Pharmaceuticals Inc.
  • Digna Biotech S.L.
  • Medivir AB
  • Amura Holdings

第12章 業界チェーンと販売チャネルの分析

  • カンジダ症治療薬 業界チェーン分析
  • カンジダ症治療薬 主要原材料分析
    • 主要原材料分析
    • 原材料の主要サプライヤー
  • カンジダ症治療薬 生産形態とプロセス
  • カンジダ症治療薬 販売およびマーケティング
    • カンジダ症治療薬 販売チャネル
    • カンジダ症治療薬 卸業者
  • カンジダ症治療薬 顧客

第13章 市場の促進要因, 機会, 課題とリスク要因の分析

  • カンジダ症治療薬 業界動向
  • カンジダ症治療薬 市場の促進要因
  • カンジダ症治療薬 市場の課題
  • カンジダ症治療薬 市場の抑制要因

第14章 世界のカンジダ症治療薬の主な市場調査結果

第15章 付録

図表
  • Table 1. Global Candidiasis Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 2. Major Manufacturers of Doxorubicin
  • Table 3. Major Manufacturers of Cisplatin
  • Table 4. Major Manufacturers of 7Carboplatin
  • Table 5. Major Manufacturers of Etoposide
  • Table 6. Major Manufacturers of Ifosfamide
  • Table 7. Major Manufacturers of Cyclophosphamide
  • Table 8. Major Manufacturers of Methotrexate
  • Table 9. Major Manufacturers of Vincristine
  • Table 10. Global Candidiasis Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 11. Global Candidiasis Therapeutics Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
  • Table 12. Global Candidiasis Therapeutics Sales by Region (2017-2022) & (K Pcs)
  • Table 13. Global Candidiasis Therapeutics Sales Market Share by Region (2017-2022)
  • Table 14. Global Candidiasis Therapeutics Sales by Region (2023-2028) & (K Pcs)
  • Table 15. Global Candidiasis Therapeutics Sales Market Share by Region (2023-2028)
  • Table 16. Global Candidiasis Therapeutics Revenue by Region (2017-2022) & (US$ Million)
  • Table 17. Global Candidiasis Therapeutics Revenue Market Share by Region (2017-2022)
  • Table 18. Global Candidiasis Therapeutics Revenue by Region (2023-2028) & (US$ Million)
  • Table 19. Global Candidiasis Therapeutics Revenue Market Share by Region (2023-2028)
  • Table 20. Global Candidiasis Therapeutics Sales by Manufacturers (2017-2022) & (K Pcs)
  • Table 21. Global Candidiasis Therapeutics Sales Share by Manufacturers (2017-2022)
  • Table 22. Global Candidiasis Therapeutics Revenue by Manufacturers (2017-2022) & (US$ Million)
  • Table 23. Global Candidiasis Therapeutics Revenue Share by Manufacturers (2017-2022)
  • Table 24. Candidiasis Therapeutics Price by Manufacturers (2017-2022) &(USD/Pcs)
  • Table 25. Global Candidiasis Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 26. Global Candidiasis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Candidiasis Therapeutics as of 2021)
  • Table 27. Candidiasis Therapeutics Manufacturing Base Distribution and Headquarters
  • Table 28. Manufacturers Candidiasis Therapeutics Product Offered
  • Table 29. Date of Manufacturers Enter into Candidiasis Therapeutics Market
  • Table 30. Mergers & Acquisitions, Expansion Plans
  • Table 31. Global Candidiasis Therapeutics Sales by Type (2017-2022) & (K Pcs)
  • Table 32. Global Candidiasis Therapeutics Sales by Type (2023-2028) & (K Pcs)
  • Table 33. Global Candidiasis Therapeutics Sales Share by Type (2017-2022)
  • Table 34. Global Candidiasis Therapeutics Sales Share by Type (2023-2028)
  • Table 35. Global Candidiasis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
  • Table 36. Global Candidiasis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
  • Table 37. Global Candidiasis Therapeutics Revenue Share by Type (2017-2022)
  • Table 38. Global Candidiasis Therapeutics Revenue Share by Type (2023-2028)
  • Table 39. Candidiasis Therapeutics Price by Type (2017-2022) & (USD/Pcs)
  • Table 40. Global Candidiasis Therapeutics Price Forecast by Type (2023-2028) & (USD/Pcs)
  • Table 41. Global Candidiasis Therapeutics Sales by Application (2017-2022) & (K Pcs)
  • Table 42. Global Candidiasis Therapeutics Sales by Application (2023-2028) & (K Pcs)
  • Table 43. Global Candidiasis Therapeutics Sales Share by Application (2017-2022)
  • Table 44. Global Candidiasis Therapeutics Sales Share by Application (2023-2028)
  • Table 45. Global Candidiasis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
  • Table 46. Global Candidiasis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
  • Table 47. Global Candidiasis Therapeutics Revenue Share by Application (2017-2022)
  • Table 48. Global Candidiasis Therapeutics Revenue Share by Application (2023-2028)
  • Table 49. Candidiasis Therapeutics Price by Application (2017-2022) & (USD/Pcs)
  • Table 50. Global Candidiasis Therapeutics Price Forecast by Application (2023-2028) & (USD/Pcs)
  • Table 51. North America Candidiasis Therapeutics Sales by Type (2017-2022) & (K Pcs)
  • Table 52. North America Candidiasis Therapeutics Sales by Type (2023-2028) & (K Pcs)
  • Table 53. North America Candidiasis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
  • Table 54. North America Candidiasis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
  • Table 55. North America Candidiasis Therapeutics Sales by Application (2017-2022) & (K Pcs)
  • Table 56. North America Candidiasis Therapeutics Sales by Application (2023-2028) & (K Pcs)
  • Table 57. North America Candidiasis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
  • Table 58. North America Candidiasis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
  • Table 59. North America Candidiasis Therapeutics Sales by Country (2017-2022) & (K Pcs)
  • Table 60. North America Candidiasis Therapeutics Sales by Country (2023-2028) & (K Pcs)
  • Table 61. North America Candidiasis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
  • Table 62. North America Candidiasis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
  • Table 63. Europe Candidiasis Therapeutics Sales by Type (2017-2022) & (K Pcs)
  • Table 64. Europe Candidiasis Therapeutics Sales by Type (2023-2028) & (K Pcs)
  • Table 65. Europe Candidiasis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
  • Table 66. Europe Candidiasis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
  • Table 67. Europe Candidiasis Therapeutics Sales by Application (2017-2022) & (K Pcs)
  • Table 68. Europe Candidiasis Therapeutics Sales by Application (2023-2028) & (K Pcs)
  • Table 69. Europe Candidiasis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
  • Table 70. Europe Candidiasis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
  • Table 71. Europe Candidiasis Therapeutics Sales by Country (2017-2022) & (K Pcs)
  • Table 72. Europe Candidiasis Therapeutics Sales by Country (2023-2028) & (K Pcs)
  • Table 73. Europe Candidiasis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
  • Table 74. Europe Candidiasis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
  • Table 75. Asia Pacific Candidiasis Therapeutics Sales by Type (2017-2022) & (K Pcs)
  • Table 76. Asia Pacific Candidiasis Therapeutics Sales by Type (2023-2028) & (K Pcs)
  • Table 77. Asia Pacific Candidiasis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
  • Table 78. Asia Pacific Candidiasis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
  • Table 79. Asia Pacific Candidiasis Therapeutics Sales by Application (2017-2022) & (K Pcs)
  • Table 80. Asia Pacific Candidiasis Therapeutics Sales by Application (2023-2028) & (K Pcs)
  • Table 81. Asia Pacific Candidiasis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
  • Table 82. Asia Pacific Candidiasis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
  • Table 83. Asia Pacific Candidiasis Therapeutics Sales by Region (2017-2022) & (K Pcs)
  • Table 84. Asia Pacific Candidiasis Therapeutics Sales by Region (2023-2028) & (K Pcs)
  • Table 85. Asia Pacific Candidiasis Therapeutics Revenue by Region (2017-2022) & (US$ Million)
  • Table 86. Asia Pacific Candidiasis Therapeutics Revenue by Region (2023-2028) & (US$ Million)
  • Table 87. Latin America Candidiasis Therapeutics Sales by Type (2017-2022) & (K Pcs)
  • Table 88. Latin America Candidiasis Therapeutics Sales by Type (2023-2028) & (K Pcs)
  • Table 89. Latin America Candidiasis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
  • Table 90. Latin America Candidiasis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
  • Table 91. Latin America Candidiasis Therapeutics Sales by Application (2017-2022) & (K Pcs)
  • Table 92. Latin America Candidiasis Therapeutics Sales by Application (2023-2028) & (K Pcs)
  • Table 93. Latin America Candidiasis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
  • Table 94. Latin America Candidiasis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
  • Table 95. Latin America Candidiasis Therapeutics Sales by Country (2017-2022) & (K Pcs)
  • Table 96. Latin America Candidiasis Therapeutics Sales by Country (2023-2028) & (K Pcs)
  • Table 97. Latin America Candidiasis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
  • Table 98. Latin America Candidiasis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
  • Table 99. Middle East and Africa Candidiasis Therapeutics Sales by Type (2017-2022) & (K Pcs)
  • Table 100. Middle East and Africa Candidiasis Therapeutics Sales by Type (2023-2028) & (K Pcs)
  • Table 101. Middle East and Africa Candidiasis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
  • Table 102. Middle East and Africa Candidiasis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
  • Table 103. Middle East and Africa Candidiasis Therapeutics Sales by Application (2017-2022) & (K Pcs)
  • Table 104. Middle East and Africa Candidiasis Therapeutics Sales by Application (2023-2028) & (K Pcs)
  • Table 105. Middle East and Africa Candidiasis Therapeutics Revenue by Application (2017-2022) & (US$ Million)
  • Table 106. Middle East and Africa Candidiasis Therapeutics Revenue by Application (2023-2028) & (US$ Million)
  • Table 107. Middle East and Africa Candidiasis Therapeutics Sales by Country (2017-2022) & (K Pcs)
  • Table 108. Middle East and Africa Candidiasis Therapeutics Sales by Country (2023-2028) & (K Pcs)
  • Table 109. Middle East and Africa Candidiasis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
  • Table 110. Middle East and Africa Candidiasis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
  • Table 111. Novartis AG Corporation Information
  • Table 112. Novartis AG Description and Major Businesses
  • Table 113. Novartis AG Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 114. Novartis AG Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 115. Novartis AG Recent Developments
  • Table 116. Amgen Corporation Information
  • Table 117. Amgen Description and Major Businesses
  • Table 118. Amgen Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 119. Amgen Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 120. Amgen Recent Developments
  • Table 121. F. Hoffmann-La Roche Ltd. Corporation Information
  • Table 122. F. Hoffmann-La Roche Ltd. Description and Major Businesses
  • Table 123. F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 124. F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 125. F. Hoffmann-La Roche Ltd. Recent Developments
  • Table 126. Bayer-Algeta Corporation Information
  • Table 127. Bayer-Algeta Description and Major Businesses
  • Table 128. Bayer-Algeta Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 129. Bayer-Algeta Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 130. Bayer-Algeta Recent Developments
  • Table 131. Merrion Pharmaceuticals Plc. Corporation Information
  • Table 132. Merrion Pharmaceuticals Plc. Description and Major Businesses
  • Table 133. Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 134. Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 135. Merrion Pharmaceuticals Plc. Recent Developments
  • Table 136. Ablynx Corporation Information
  • Table 137. Ablynx Description and Major Businesses
  • Table 138. Ablynx Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 139. Ablynx Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 140. Ablynx Recent Developments
  • Table 141. Genta Incorporated Corporation Information
  • Table 142. Genta Incorporated Description and Major Businesses
  • Table 143. Genta Incorporated Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 144. Genta Incorporated Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 145. Genta Incorporated Recent Developments
  • Table 146. Galapagos NV Corporation Information
  • Table 147. Galapagos NV Description and Major Businesses
  • Table 148. Galapagos NV Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 149. Galapagos NV Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 150. Galapagos NV Recent Developments
  • Table 151. Catena Pharmaceuticals Inc. Corporation Information
  • Table 152. Catena Pharmaceuticals Inc. Description and Major Businesses
  • Table 153. Catena Pharmaceuticals Inc. Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 154. Catena Pharmaceuticals Inc. Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 155. Catena Pharmaceuticals Inc. Recent Developments
  • Table 156. Digna Biotech S.L. Corporation Information
  • Table 157. Digna Biotech S.L. Description and Major Businesses
  • Table 158. Digna Biotech S.L. Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 159. Digna Biotech S.L. Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 160. Digna Biotech S.L. Recent Developments
  • Table 161. Medivir AB Corporation Information
  • Table 162. Medivir AB Description and Major Businesses
  • Table 163. Medivir AB Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 164. Medivir AB Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 165. Medivir AB Recent Developments
  • Table 166. Amura Holdings Corporation Information
  • Table 167. Amura Holdings Description and Major Businesses
  • Table 168. Amura Holdings Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
  • Table 169. Amura Holdings Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 170. Amura Holdings Recent Developments
  • Table 171. Key Raw Materials Lists
  • Table 172. Raw Materials Key Suppliers Lists
  • Table 173. Candidiasis Therapeutics Distributors List
  • Table 174. Candidiasis Therapeutics Customers List
  • Table 175. Candidiasis Therapeutics Market Trends
  • Table 176. Candidiasis Therapeutics Market Drivers
  • Table 177. Candidiasis Therapeutics Market Challenges
  • Table 178. Candidiasis Therapeutics Market Restraints
  • Table 179. Research Programs/Design for This Report
  • Table 180. Key Data Information from Secondary Sources
  • Table 181. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Candidiasis Therapeutics Product Picture
  • Figure 3. Global Candidiasis Therapeutics Market Share by Type in 2021 & 2028
  • Figure 3. Doxorubicin Product Picture
  • Figure 4. Cisplatin Product Picture
  • Figure 5. 7Carboplatin Product Picture
  • Figure 6. Etoposide Product Picture
  • Figure 7. Ifosfamide Product Picture
  • Figure 8. Cyclophosphamide Product Picture
  • Figure 9. Methotrexate Product Picture
  • Figure 10. Vincristine Product Picture
  • Figure 11. Global Candidiasis Therapeutics Market Share by Application in 2021 & 2028
  • Figure 12. Multispecialty Hospitals
  • Figure 13. Cancer Research Institutes
  • Figure 14. Others
  • Figure 15. Candidiasis Therapeutics Report Years Considered
  • Figure 16. Global Candidiasis Therapeutics Sales 2017-2028 (K Pcs)
  • Figure 17. Global Candidiasis Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 18. Global Candidiasis Therapeutics Revenue 2017-2028 (US$ Million)
  • Figure 19. Global Candidiasis Therapeutics Revenue Market Share by Region in Percentage: 2021 Versus 2028
  • Figure 20. Global Candidiasis Therapeutics Sales Market Share by Region (2017-2022)
  • Figure 21. Global Candidiasis Therapeutics Sales Market Share by Region (2023-2028)
  • Figure 22. North America Candidiasis Therapeutics Sales YoY (2017-2028) & (K Pcs)
  • Figure 23. North America Candidiasis Therapeutics Revenue YoY (2017-2028) & (US$ Million)
  • Figure 24. Europe Candidiasis Therapeutics Sales YoY (2017-2028) & (K Pcs)
  • Figure 25. Europe Candidiasis Therapeutics Revenue YoY (2017-2028) & (US$ Million)
  • Figure 26. Asia-Pacific Candidiasis Therapeutics Sales YoY (2017-2028) & (K Pcs)
  • Figure 27. Asia-Pacific Candidiasis Therapeutics Revenue YoY (2017-2028) & (US$ Million)
  • Figure 28. Latin America Candidiasis Therapeutics Sales YoY (2017-2028) & (K Pcs)
  • Figure 29. Latin America Candidiasis Therapeutics Revenue YoY (2017-2028) & (US$ Million)
  • Figure 30. Middle East & Africa Candidiasis Therapeutics Sales YoY (2017-2028) & (K Pcs)
  • Figure 31. Middle East & Africa Candidiasis Therapeutics Revenue YoY (2017-2028) & (US$ Million)
  • Figure 32. The Candidiasis Therapeutics Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
  • Figure 33. The Top 5 and 10 Largest Manufacturers of Candidiasis Therapeutics in the World: Market Share by Candidiasis Therapeutics Revenue in 2021
  • Figure 34. Global Candidiasis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
  • Figure 35. Global Candidiasis Therapeutics Sales Market Share by Type (2017-2028)
  • Figure 36. Global Candidiasis Therapeutics Revenue Market Share by Type (2017-2028)
  • Figure 37. Global Candidiasis Therapeutics Sales Market Share by Application (2017-2028)
  • Figure 38. Global Candidiasis Therapeutics Revenue Market Share by Application (2017-2028)
  • Figure 39. North America Candidiasis Therapeutics Sales Market Share by Type (2017-2028)
  • Figure 40. North America Candidiasis Therapeutics Revenue Market Share by Type (2017-2028)
  • Figure 41. North America Candidiasis Therapeutics Sales Market Share by Application (2017-2028)
  • Figure 42. North America Candidiasis Therapeutics Revenue Market Share by Application (2017-2028)
  • Figure 43. North America Candidiasis Therapeutics Sales Share by Country (2017-2028)
  • Figure 44. North America Candidiasis Therapeutics Revenue Share by Country (2017-2028)
  • Figure 45. U.S. Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 46. Canada Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 47. Europe Candidiasis Therapeutics Sales Market Share by Type (2017-2028)
  • Figure 48. Europe Candidiasis Therapeutics Revenue Market Share by Type (2017-2028)
  • Figure 49. Europe Candidiasis Therapeutics Sales Market Share by Application (2017-2028)
  • Figure 50. Europe Candidiasis Therapeutics Revenue Market Share by Application (2017-2028)
  • Figure 51. Europe Candidiasis Therapeutics Sales Share by Country (2017-2028)
  • Figure 52. Europe Candidiasis Therapeutics Revenue Share by Country (2017-2028)
  • Figure 53. Germany Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 54. France Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 55. U.K. Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 56. Italy Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 57. Russia Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 58. Asia Pacific Candidiasis Therapeutics Sales Market Share by Type (2017-2028)
  • Figure 59. Asia Pacific Candidiasis Therapeutics Revenue Market Share by Type (2017-2028)
  • Figure 60. Asia Pacific Candidiasis Therapeutics Sales Market Share by Application (2017-2028)
  • Figure 61. Asia Pacific Candidiasis Therapeutics Revenue Market Share by Application (2017-2028)
  • Figure 62. Asia Pacific Candidiasis Therapeutics Sales Share by Region (2017-2028)
  • Figure 63. Asia Pacific Candidiasis Therapeutics Revenue Share by Region (2017-2028)
  • Figure 64. China Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 65. Japan Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 66. South Korea Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 67. India Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 68. Australia Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 69. Taiwan Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 70. Indonesia Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 71. Thailand Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 72. Malaysia Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 73. Philippines Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 74. Latin America Candidiasis Therapeutics Sales Market Share by Type (2017-2028)
  • Figure 75. Latin America Candidiasis Therapeutics Revenue Market Share by Type (2017-2028)
  • Figure 76. Latin America Candidiasis Therapeutics Sales Market Share by Application (2017-2028)
  • Figure 77. Latin America Candidiasis Therapeutics Revenue Market Share by Application (2017-2028)
  • Figure 78. Latin America Candidiasis Therapeutics Sales Share by Country (2017-2028)
  • Figure 79. Latin America Candidiasis Therapeutics Revenue Share by Country (2017-2028)
  • Figure 80. Mexico Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 81. Brazil Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 82. Argentina Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 83. Middle East and Africa Candidiasis Therapeutics Sales Market Share by Type (2017-2028)
  • Figure 84. Middle East and Africa Candidiasis Therapeutics Revenue Market Share by Type (2017-2028)
  • Figure 85. Middle East and Africa Candidiasis Therapeutics Sales Market Share by Application (2017-2028)
  • Figure 86. Middle East and Africa Candidiasis Therapeutics Revenue Market Share by Application (2017-2028)
  • Figure 87. Middle East and Africa Candidiasis Therapeutics Sales Share by Country (2017-2028)
  • Figure 88. Middle East and Africa Candidiasis Therapeutics Revenue Share by Country (2017-2028)
  • Figure 89. Turkey Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 90. Saudi Arabia Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 91. UAE Candidiasis Therapeutics Revenue (2017-2028) & (US$ Million)
  • Figure 92. Candidiasis Therapeutics Value Chain
  • Figure 93. Candidiasis Therapeutics Production Process
  • Figure 94. Channels of Distribution
  • Figure 95. Distributors Profiles
  • Figure 96. Bottom-up and Top-down Approaches for This Report
  • Figure 97. Data Triangulation
  • Figure 98. Key Executives Interviewed
目次

This research report focuses on the Candidiasis Therapeutics Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 Candidiasis Therapeutics Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Candidiasis Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Doxorubicin
    • 1.2.3 Cisplatin
    • 1.2.4 7Carboplatin
    • 1.2.5 Etoposide
    • 1.2.6 Ifosfamide
    • 1.2.7 Cyclophosphamide
    • 1.2.8 Methotrexate
    • 1.2.9 Vincristine
  • 1.3 Market by Application
    • 1.3.1 Global Candidiasis Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Multispecialty Hospitals
    • 1.3.3 Cancer Research Institutes
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global Candidiasis Therapeutics Sales Estimates and Forecasts 2017-2028
  • 2.2 Global Candidiasis Therapeutics Revenue Estimates and Forecasts 2017-2028
  • 2.3 Global Candidiasis Therapeutics Revenue by Region: 2017 VS 2021 VS 2028
  • 2.4 Global Candidiasis Therapeutics Sales by Region
    • 2.4.1 Global Candidiasis Therapeutics Sales by Region (2017-2022)
    • 2.4.2 Global Sales Candidiasis Therapeutics by Region (2023-2028)
  • 2.5 Global Candidiasis Therapeutics Revenue by Region
    • 2.5.1 Global Candidiasis Therapeutics Revenue by Region (2017-2022)
    • 2.5.2 Global Candidiasis Therapeutics Revenue by Region (2023-2028)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global Candidiasis Therapeutics Sales by Manufacturers
    • 3.1.1 Global Top Candidiasis Therapeutics Manufacturers by Sales (2017-2022)
    • 3.1.2 Global Candidiasis Therapeutics Sales Market Share by Manufacturers (2017-2022)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Candidiasis Therapeutics in 2021
  • 3.2 Global Candidiasis Therapeutics Revenue by Manufacturers
    • 3.2.1 Global Candidiasis Therapeutics Revenue by Manufacturers (2017-2022)
    • 3.2.2 Global Candidiasis Therapeutics Revenue Market Share by Manufacturers (2017-2022)
    • 3.2.3 Global Top 10 and Top 5 Companies by Candidiasis Therapeutics Revenue in 2021
  • 3.3 Global Candidiasis Therapeutics Sales Price by Manufacturers (2017-2022)
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Candidiasis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global Candidiasis Therapeutics Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Candidiasis Therapeutics Sales by Type
    • 4.1.1 Global Candidiasis Therapeutics Historical Sales by Type (2017-2022)
    • 4.1.2 Global Candidiasis Therapeutics Forecasted Sales by Type (2023-2028)
    • 4.1.3 Global Candidiasis Therapeutics Sales Market Share by Type (2017-2028)
  • 4.2 Global Candidiasis Therapeutics Revenue by Type
    • 4.2.1 Global Candidiasis Therapeutics Historical Revenue by Type (2017-2022)
    • 4.2.2 Global Candidiasis Therapeutics Forecasted Revenue by Type (2023-2028)
    • 4.2.3 Global Candidiasis Therapeutics Revenue Market Share by Type (2017-2028)
  • 4.3 Global Candidiasis Therapeutics Price by Type
    • 4.3.1 Global Candidiasis Therapeutics Price by Type (2017-2022)
    • 4.3.2 Global Candidiasis Therapeutics Price Forecast by Type (2023-2028)

5 Market Size by Application

  • 5.1 Global Candidiasis Therapeutics Sales by Application
    • 5.1.1 Global Candidiasis Therapeutics Historical Sales by Application (2017-2022)
    • 5.1.2 Global Candidiasis Therapeutics Forecasted Sales by Application (2023-2028)
    • 5.1.3 Global Candidiasis Therapeutics Sales Market Share by Application (2017-2028)
  • 5.2 Global Candidiasis Therapeutics Revenue by Application
    • 5.2.1 Global Candidiasis Therapeutics Historical Revenue by Application (2017-2022)
    • 5.2.2 Global Candidiasis Therapeutics Forecasted Revenue by Application (2023-2028)
    • 5.2.3 Global Candidiasis Therapeutics Revenue Market Share by Application (2017-2028)
  • 5.3 Global Candidiasis Therapeutics Price by Application
    • 5.3.1 Global Candidiasis Therapeutics Price by Application (2017-2022)
    • 5.3.2 Global Candidiasis Therapeutics Price Forecast by Application (2023-2028)

6 North America

  • 6.1 North America Candidiasis Therapeutics Market Size by Type
    • 6.1.1 North America Candidiasis Therapeutics Sales by Type (2017-2028)
    • 6.1.2 North America Candidiasis Therapeutics Revenue by Type (2017-2028)
  • 6.2 North America Candidiasis Therapeutics Market Size by Application
    • 6.2.1 North America Candidiasis Therapeutics Sales by Application (2017-2028)
    • 6.2.2 North America Candidiasis Therapeutics Revenue by Application (2017-2028)
  • 6.3 North America Candidiasis Therapeutics Market Size by Country
    • 6.3.1 North America Candidiasis Therapeutics Sales by Country (2017-2028)
    • 6.3.2 North America Candidiasis Therapeutics Revenue by Country (2017-2028)
    • 6.3.3 U.S.
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe Candidiasis Therapeutics Market Size by Type
    • 7.1.1 Europe Candidiasis Therapeutics Sales by Type (2017-2028)
    • 7.1.2 Europe Candidiasis Therapeutics Revenue by Type (2017-2028)
  • 7.2 Europe Candidiasis Therapeutics Market Size by Application
    • 7.2.1 Europe Candidiasis Therapeutics Sales by Application (2017-2028)
    • 7.2.2 Europe Candidiasis Therapeutics Revenue by Application (2017-2028)
  • 7.3 Europe Candidiasis Therapeutics Market Size by Country
    • 7.3.1 Europe Candidiasis Therapeutics Sales by Country (2017-2028)
    • 7.3.2 Europe Candidiasis Therapeutics Revenue by Country (2017-2028)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific Candidiasis Therapeutics Market Size by Type
    • 8.1.1 Asia Pacific Candidiasis Therapeutics Sales by Type (2017-2028)
    • 8.1.2 Asia Pacific Candidiasis Therapeutics Revenue by Type (2017-2028)
  • 8.2 Asia Pacific Candidiasis Therapeutics Market Size by Application
    • 8.2.1 Asia Pacific Candidiasis Therapeutics Sales by Application (2017-2028)
    • 8.2.2 Asia Pacific Candidiasis Therapeutics Revenue by Application (2017-2028)
  • 8.3 Asia Pacific Candidiasis Therapeutics Market Size by Region
    • 8.3.1 Asia Pacific Candidiasis Therapeutics Sales by Region (2017-2028)
    • 8.3.2 Asia Pacific Candidiasis Therapeutics Revenue by Region (2017-2028)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia
    • 8.3.12 Philippines

9 Latin America

  • 9.1 Latin America Candidiasis Therapeutics Market Size by Type
    • 9.1.1 Latin America Candidiasis Therapeutics Sales by Type (2017-2028)
    • 9.1.2 Latin America Candidiasis Therapeutics Revenue by Type (2017-2028)
  • 9.2 Latin America Candidiasis Therapeutics Market Size by Application
    • 9.2.1 Latin America Candidiasis Therapeutics Sales by Application (2017-2028)
    • 9.2.2 Latin America Candidiasis Therapeutics Revenue by Application (2017-2028)
  • 9.3 Latin America Candidiasis Therapeutics Market Size by Country
    • 9.3.1 Latin America Candidiasis Therapeutics Sales by Country (2017-2028)
    • 9.3.2 Latin America Candidiasis Therapeutics Revenue by Country (2017-2028)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

10 Middle East and Africa

  • 10.1 Middle East and Africa Candidiasis Therapeutics Market Size by Type
    • 10.1.1 Middle East and Africa Candidiasis Therapeutics Sales by Type (2017-2028)
    • 10.1.2 Middle East and Africa Candidiasis Therapeutics Revenue by Type (2017-2028)
  • 10.2 Middle East and Africa Candidiasis Therapeutics Market Size by Application
    • 10.2.1 Middle East and Africa Candidiasis Therapeutics Sales by Application (2017-2028)
    • 10.2.2 Middle East and Africa Candidiasis Therapeutics Revenue by Application (2017-2028)
  • 10.3 Middle East and Africa Candidiasis Therapeutics Market Size by Country
    • 10.3.1 Middle East and Africa Candidiasis Therapeutics Sales by Country (2017-2028)
    • 10.3.2 Middle East and Africa Candidiasis Therapeutics Revenue by Country (2017-2028)
    • 10.3.3 Turkey
    • 10.3.4 Saudi Arabia

11 Company Profiles

  • 11.1 Novartis AG
    • 11.1.1 Novartis AG Corporation Information
    • 11.1.2 Novartis AG Overview
    • 11.1.3 Novartis AG Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.1.4 Novartis AG Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 Novartis AG Recent Developments
  • 11.2 Amgen
    • 11.2.1 Amgen Corporation Information
    • 11.2.2 Amgen Overview
    • 11.2.3 Amgen Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.2.4 Amgen Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 Amgen Recent Developments
  • 11.3 F. Hoffmann-La Roche Ltd.
    • 11.3.1 F. Hoffmann-La Roche Ltd. Corporation Information
    • 11.3.2 F. Hoffmann-La Roche Ltd. Overview
    • 11.3.3 F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.3.4 F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  • 11.4 Bayer-Algeta
    • 11.4.1 Bayer-Algeta Corporation Information
    • 11.4.2 Bayer-Algeta Overview
    • 11.4.3 Bayer-Algeta Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.4.4 Bayer-Algeta Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 Bayer-Algeta Recent Developments
  • 11.5 Merrion Pharmaceuticals Plc.
    • 11.5.1 Merrion Pharmaceuticals Plc. Corporation Information
    • 11.5.2 Merrion Pharmaceuticals Plc. Overview
    • 11.5.3 Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.5.4 Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 Merrion Pharmaceuticals Plc. Recent Developments
  • 11.6 Ablynx
    • 11.6.1 Ablynx Corporation Information
    • 11.6.2 Ablynx Overview
    • 11.6.3 Ablynx Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.6.4 Ablynx Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 Ablynx Recent Developments
  • 11.7 Genta Incorporated
    • 11.7.1 Genta Incorporated Corporation Information
    • 11.7.2 Genta Incorporated Overview
    • 11.7.3 Genta Incorporated Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.7.4 Genta Incorporated Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.7.5 Genta Incorporated Recent Developments
  • 11.8 Galapagos NV
    • 11.8.1 Galapagos NV Corporation Information
    • 11.8.2 Galapagos NV Overview
    • 11.8.3 Galapagos NV Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.8.4 Galapagos NV Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.8.5 Galapagos NV Recent Developments
  • 11.9 Catena Pharmaceuticals Inc.
    • 11.9.1 Catena Pharmaceuticals Inc. Corporation Information
    • 11.9.2 Catena Pharmaceuticals Inc. Overview
    • 11.9.3 Catena Pharmaceuticals Inc. Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.9.4 Catena Pharmaceuticals Inc. Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.9.5 Catena Pharmaceuticals Inc. Recent Developments
  • 11.10 Digna Biotech S.L.
    • 11.10.1 Digna Biotech S.L. Corporation Information
    • 11.10.2 Digna Biotech S.L. Overview
    • 11.10.3 Digna Biotech S.L. Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.10.4 Digna Biotech S.L. Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.10.5 Digna Biotech S.L. Recent Developments
  • 11.11 Medivir AB
    • 11.11.1 Medivir AB Corporation Information
    • 11.11.2 Medivir AB Overview
    • 11.11.3 Medivir AB Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.11.4 Medivir AB Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.11.5 Medivir AB Recent Developments
  • 11.12 Amura Holdings
    • 11.12.1 Amura Holdings Corporation Information
    • 11.12.2 Amura Holdings Overview
    • 11.12.3 Amura Holdings Candidiasis Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.12.4 Amura Holdings Candidiasis Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.12.5 Amura Holdings Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 Candidiasis Therapeutics Industry Chain Analysis
  • 12.2 Candidiasis Therapeutics Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Candidiasis Therapeutics Production Mode & Process
  • 12.4 Candidiasis Therapeutics Sales and Marketing
    • 12.4.1 Candidiasis Therapeutics Sales Channels
    • 12.4.2 Candidiasis Therapeutics Distributors
  • 12.5 Candidiasis Therapeutics Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 Candidiasis Therapeutics Industry Trends
  • 13.2 Candidiasis Therapeutics Market Drivers
  • 13.3 Candidiasis Therapeutics Market Challenges
  • 13.4 Candidiasis Therapeutics Market Restraints

14 Key Findings in The Global Candidiasis Therapeutics Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer